Verrica Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
YCANTH has achieved strong commercial growth with expanding market penetration and robust support programs. International expansion is progressing, and the pipeline includes a large common warts program and a promising basal cell carcinoma candidate, VP-315, with significant clinical and commercial potential.
-
Q1 2026 saw record growth in YCANTH demand, with revenue up 25% year-over-year and strong momentum into Q2. The company advanced its clinical pipeline, launched YCANTH in Japan, and is preparing for EU expansion, while maintaining a solid cash position to fund operations into 2027.
-
YCANTH continues to drive revenue growth through expanded access and clinician adoption, with a robust pipeline targeting common warts and basal cell carcinoma. Phase III trials for both indications are progressing, supported by strong financials and strategic partnerships.
-
YCANTH has rapidly gained adoption by addressing a major unmet need in molluscum contagiosum, with expanded access, streamlined distribution, and a growing, collaborative sales force. The pipeline includes a phase III program for common warts and a promising Basal Cell Carcinoma candidate, supporting long-term growth.
Fiscal Year 2025
-
2025 saw a dramatic turnaround with over 130% YCANTH revenue growth, a 368% rise in total revenue, and a strengthened balance sheet. Clinical and commercial progress positions the company for further expansion in 2026, with ongoing global trials and new market entries.
-
A commercial-stage dermatology company reported strong growth for its FDA-approved molluscum treatment, expanded access, and robust insurance coverage. Key pipeline assets include a phase III-ready program for common warts and a late-stage candidate for basal cell carcinoma, both addressing large markets.
-
Q2 2025 saw record YCANTH growth, a major Torii partnership expansion, and a return to profitability. Revenue rose to $12.7M, driven by milestone payments and strong commercial execution, with further growth and milestone payments expected in the second half of 2025.
-
YCANTH, a novel in-office treatment for molluscum, is driving strong growth and expanding access through a new specialty pharmacy model and improved reimbursement. The company is targeting operational break-even by year-end, with a robust pipeline and key milestones ahead.
-
Q1 2025 saw 16.7% sequential growth in YCANTH units and $3.4M revenue, with improved margins and reduced expenses. Cash runway depends on milestone payments or warrant exercises, while clinical and commercial momentum continues in both dermatology and oncology.
-
A new management team executed a cost-efficient relaunch of YCANTH, achieving strong sequential growth and expanded access through specialty pharmacy and insurance coverage. Pipeline programs for basal cell carcinoma and common warts are advancing, with significant market opportunities and co-funding partnerships.
-
A major restructuring and commercial strategy shift have driven improved sales and operational efficiency, with Ycanth gaining traction in the molluscum market. Pipeline progress includes a global phase 3 program for common warts and promising phase 2 results in basal cell carcinoma.
-
New leadership has restructured operations, secured funding, and implemented a focused commercial strategy for YCANTH, targeting both dermatologists and pediatricians. Pipeline expansion includes a global phase III program for common warts and promising data for VP-315 in basal cell carcinoma.
Fiscal Year 2024
-
Q4 2024 saw a successful turnaround with cost reductions, sequential growth in YCANTH units, and a $42M capital raise. Full-year revenue rose to $7.6M, with strong gross margins and expanding pediatric adoption. Cash runway depends on milestone payments and prudent management.
-
Promising phase II data for VP-315 in basal cell carcinoma positions it as a non-invasive alternative to surgery, with expansion potential into squamous cell carcinoma. YCANTH's launch faces logistical hurdles but maintains strong coverage and physician support, while market opportunities in molluscum and warts remain significant.
-
Q2 2024 revenue reached $5.2M, driven by YCANTH growth and expanded coverage. Positive Phase 2 data for VP-315 in basal cell carcinoma was announced. Settlement to remove compounded cantharidin is expected to boost YCANTH demand as inventory depletes.
-
Q1 revenues rose to $3.2M, driven by increased demand and expanded coverage. The launch of YCANTH, the first FDA-approved molluscum treatment, is supported by a growing sales force and improved reimbursement, with a 42% uptick in buy-and-bill accounts after J-Code publication.